Acute Ischemic Stroke - Pipeline Review, H1 2016

  • ID: 3714964
  • Drug Pipelines
  • 131 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AB Science SA
  • AstraZeneca Plc
  • Biogen, Inc.
  • DiaMedica Inc.
  • Digna Biotech, S.L.
  • D-Pharm Ltd.
  • MORE
Acute Ischemic Stroke - Pipeline Review, H1 2016

Summary

‘Acute Ischemic Stroke - Pipeline Review, H1 2016’, provides an overview of the Acute Ischemic Stroke pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Ischemic Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Ischemic Stroke and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Ischemic Stroke
- The report reviews pipeline therapeutics for Acute Ischemic Stroke by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acute Ischemic Stroke therapeutics and enlists all their major and minor projects
- The report assesses Acute Ischemic Stroke therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acute Ischemic Stroke

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acute Ischemic Stroke
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acute Ischemic Stroke pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AB Science SA
  • AstraZeneca Plc
  • Biogen, Inc.
  • DiaMedica Inc.
  • Digna Biotech, S.L.
  • D-Pharm Ltd.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Acute Ischemic Stroke Overview

Therapeutics Development

Pipeline Products for Acute Ischemic Stroke - Overview

Acute Ischemic Stroke - Therapeutics under Development by Companies

Acute Ischemic Stroke - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Acute Ischemic Stroke - Products under Development by Companies

Acute Ischemic Stroke - Companies Involved in Therapeutics Development

AB Science SA

AstraZeneca Plc

Biogen, Inc.

D-Pharm Ltd.

Daiichi Sankyo Company, Limited

DiaMedica Inc.

Digna Biotech, S.L.

Glucox Biotech AB

Grifols, S.A.

Lumosa Therapeutics Co., Ltd.

Mitsubishi Tanabe Pharma Corporation

Pharmicell Co., Ltd.

PhytoHealth Corporation

Remedy Pharmaceuticals, Inc.

Saneron CCEL Therapeutics, Inc.

Simcere Pharmaceutical Group

Stemedica Cell Technologies, Inc.

Acute Ischemic Stroke - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

3K3A-APC - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ApTLR-4FT - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cellgram-IS - Drug Profile

Product Description

Mechanism of Action

R&D Progress

DB-017 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

DM-199 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

DS-1040 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

glyburide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

HBI-002 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

HBN-1 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Human Umbilical Cord Blood Cell Therapy for Neurological and Cardiovascular Diseases - Drug Profile

Product Description

Mechanism of Action

R&D Progress

LT-3001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

masitinib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MP-124 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

natalizumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PHN-014 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Rejuveinix - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SIM-071201 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TAL-0500018 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

THR-18 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ticagrelor - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TMS-007 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Acute Ischemic Stroke - Recent Pipeline Updates

Acute Ischemic Stroke - Dormant Projects

Acute Ischemic Stroke - Discontinued Products

Acute Ischemic Stroke - Product Development Milestones

Featured News & Press Releases

Feb 02, 2016: DiaMedica Provides Update on DM199 Opportunity in South East Asia

Jan 05, 2016: CNS-Related Edema Company Remedy Pharmaceuticals Strengthens Leadership Team in Preparation for Phase 3 Trial

Nov 04, 2015: DiaMedica Provides Corporate Update

Oct 09, 2015: Remedy Pharmaceuticals’ Drug CIRARA™ Cut Death Rates from Severe Stroke by More Than Half

Sep 29, 2015: Remedy Pharmaceuticals Announces Phase 2 Severe Stroke Study Results to Be Presented at Neurocritical Care Annual Meeting

Mar 19, 2015: DiaMedica to Present at the 12th Annual BIO Asia International Conference

Dec 18, 2014: D-Pharm Achieves Primary End-point in Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated With tPA

Nov 04, 2014: D-Pharm Reports First Results From its Phase 2 Clinical Study of THR-18 In Acute Stroke Patients Treated with tPA

Aug 19, 2014: US Department of Justice Closes Investigation into PLATO Clinical Trial for BRILINTA

Jun 02, 2014: D-Pharm Reports Completion of the Second Dose Tier in its Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated with the Thrombolytic Drug tPA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Acute Ischemic Stroke, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Acute Ischemic Stroke - Pipeline by AB Science SA, H1 2016

Acute Ischemic Stroke - Pipeline by AstraZeneca Plc, H1 2016

Acute Ischemic Stroke - Pipeline by Biogen, Inc., H1 2016

Acute Ischemic Stroke - Pipeline by D-Pharm Ltd., H1 2016

Acute Ischemic Stroke - Pipeline by Daiichi Sankyo Company, Limited, H1 2016

Acute Ischemic Stroke - Pipeline by DiaMedica Inc., H1 2016

Acute Ischemic Stroke - Pipeline by Digna Biotech, S.L., H1 2016

Acute Ischemic Stroke - Pipeline by Glucox Biotech AB, H1 2016

Acute Ischemic Stroke - Pipeline by Grifols, S.A., H1 2016

Acute Ischemic Stroke - Pipeline by Lumosa Therapeutics Co., Ltd., H1 2016

Acute Ischemic Stroke - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016

Acute Ischemic Stroke - Pipeline by Pharmicell Co., Ltd., H1 2016

Acute Ischemic Stroke - Pipeline by PhytoHealth Corporation, H1 2016

Acute Ischemic Stroke - Pipeline by Remedy Pharmaceuticals, Inc., H1 2016

Acute Ischemic Stroke - Pipeline by Saneron CCEL Therapeutics, Inc., H1 2016

Acute Ischemic Stroke - Pipeline by Simcere Pharmaceutical Group, H1 2016

Acute Ischemic Stroke - Pipeline by Stemedica Cell Technologies, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Acute Ischemic Stroke Therapeutics - Recent Pipeline Updates, H1 2016

Acute Ischemic Stroke - Dormant Projects, H1 2016

Acute Ischemic Stroke - Dormant Projects (Contd..1), H1 2016

Acute Ischemic Stroke - Discontinued Products, H1 2016

Acute Ischemic Stroke - Discontinued Products (Contd..1), H1 2016

List of Figures

Number of Products under Development for Acute Ischemic Stroke, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
AB Science SA
AstraZeneca Plc
Biogen, Inc.
D-Pharm Ltd.
Daiichi Sankyo Company, Limited
DiaMedica Inc.
Digna Biotech, S.L.
Glucox Biotech AB
Grifols, S.A.
Lumosa Therapeutics Co., Ltd.
Mitsubishi Tanabe Pharma Corporation
Pharmicell Co., Ltd.
PhytoHealth Corporation
Remedy Pharmaceuticals, Inc.
Saneron CCEL Therapeutics, Inc.
Simcere Pharmaceutical Group
Stemedica Cell Technologies, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll